secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001372514-23-000103
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Pharma 2023 annual meeting results: all proposals approved
----------------------------------------------------------------

- Kenneth Gayron, Aron Shapiro, Praveen Tyle elected as Class II directors (3-year term, through 2026).
- Non-binding advisory vote on executive compensation passed: 243,595 for, 43,492 against, 8,996 abstain.
- Ratification of Haskell & White LLP as independent auditor ratified: 798,689 for, 14,659 against, 19,738 abstain.
- Total shares voted at meeting: approximately 1.1M (including broker non-votes).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000103/0001372514-23-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000103/kprx-20230621.htm
  HTML page:      https://secwatch.observer/filing/0001372514-23-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer